eResearch Posts Perspective on Microbix Biosystems Inc.


Follow this company

Companies Mentioned

TSX:MBX
01/08/2014 [ACCESSWIRE] Microbix Biosystems Inc. focuses on developing and commercializing biological products and technologies through leveraging its Core Base Business of developing infectious disease antigens (virology) for sale to large diagnostic kit manufacturers.  

The Company has reported Q4 and full-year F2013 results, with revenue for F2013 up 14% compared with F2012. Microbix has provided updates on its thrombolytic drug Kinlytic™ (Urokinase) as well as announcing patent litigation against Novartis Vaccines and Diagnostics. 

Read more in the Perspective here:  Microbix Biosystems 

eResearch is a primary source for professional investment research, focused on small- and mid-cap companies. Our research and analysis is of institutional quality, and has the potential for reaching millions of global investors through our extensive electronic distribution network. 

eResearch posts all its reports and articles on its website, eresearch.ca, and subscription is FREE. 

Contact:

eResearch: Bob Weir, CFA, Director of Research
Telephone: (416) 703-6258
email: bweir@eresearch.ca

COMMENTS

Leave a comment...
 * 

Your Name
 *